Regeneron Pharmaceuticals, Inc.NASDAQ: REGN

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

· Issued by Regeneron Pharmaceuticals, Inc.
Watch Regeneron Pharmaceuticals explain itRegeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call · Replay · Jul 30

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p

Company analysis